Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509316 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL15263324 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL2010790 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL4436402 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL5182595 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL240028 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL1994115 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL9393256 | 1.00 | HIF1A (0.43) | HIF1AADORA2AADORA2BLMNANT5E | |
| Water SCHEMBL5144372 | 0.99 | HIF1A (0.42) | HIF1AADORA2AADORA2BLMNANT5E | |
| SCHEMBL7643809 | 0.90 | PYGL (0.38) | HIF1AADORA2AADORA2BLMNANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113980076-A | Flame retardant and preparation method thereof | 盐城工业职业技术学院 | 2022-01-28 | — | — | CN | claimed |
| WO-2018075264-A1 | CHEMICALLY MODIFIED RNA APTAMERS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2014011465-A2 | APTAMER-TARGETED ANTIGEN DELIVERY | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2013163303-A2 | TRANSFERRIN RECEPTOR APTAMERS AND APTAMER-TARGETED DELIVERY | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-10-31 | — | — | WO | disclosed |
| WO-2011142798-A2 | METHODS OF PREPARING TARGETED APTAMER PRODRUGS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | HIF1A 698/4885ADORA2A 33/4885ADORA2B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.